Login | Register

Virus-Based Melanoma Drug Shows Promise In Trial

For the first time in a late stage trial, a virus-based cancer drug is showing some promising early results. The news that Amgen's melanoma drug talimogene laherparepvec (TVEC) has met the primary goal of a Phase 3 trial may revive interest in what has proved to be a rather elusive drug technology...

Read More

Leave a Reply

Your email address will not be published. Required fields are marked *